MMP9 and myeloid sarcoma: Similarly, the angiotensin II receptor antagonist candesartan inhibits TGF-β1-induced MMP9 via Smad7 Yu et al., [79], therefore, angiotensin antagonists may also be able to suppress the vessel remodeling that can contribute to vascular abnormalities in MS.